RxDoctor Payments Data

Jill Gilbert, APRN

Family · Spring Hill, FLNPI 1134898943

Payments from drug & device makers

$12,101in general payments, 2019–2025

Across 489 payments — averaging $24.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Gilead$885
  • Seagen Inc.$708
  • Johnson & Johnson$666
  • Pfizer$573
  • Merck$571
  • plus $8K from 53 others

What the payments were for

  • Food & beverage$10,98291%
  • Education$1,1199%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis62$1,143
Gilead(2 entities)39$885
Seagen Inc.23$708
Johnson & Johnson26$666
Pfizer31$573
Merck27$571
AstraZeneca(2 entities)25$549
Astellas Pharma US Inc15$546
Incyte Corporation20$523
Sanofi15$517
Lilly USA, LLC19$493
Eisai Inc.22$447
Genentech USA, Inc.5$362
AVEO Pharmaceuticals, Inc.10$358
E.r. Squibb & Sons, L.L.C.11$308
Sobi, Inc7$264
Bayer11$263
Rigel Pharmaceuticals, Inc.1$248
AbbVie9$233
Bristol Myers Squibb8$224
Takeda Pharmaceuticals U.S.A., Inc.6$171
GSK8$160
Daiichi Sankyo Inc.5$125
Puma Biotechnology, Inc.6$118
Array Biopharma Inc6$109
EMD Serono, Inc.5$97
Legend Biotech USA Inc.3$94
Dendreon Pharmaceuticals LLC3$93
Regeneron Healthcare Solutions, Inc.3$87
Jazz Pharmaceuticals Inc.5$84
Pharmacosmos Therapeutics Inc.4$83
Amgen4$77
Geron Corporation3$69
Ipsen Biopharmaceuticals, Inc3$67
Beone Medicines USA, Inc.2$55
Stemline Therapeutics Inc.2$48
Kyowa Kirin, Inc.2$48
AMAG Pharmaceuticals, Inc.2$45
Pharmaessentia USA Corporation2$44
GE HealthCare2$44
Blueprint Medicines Corporation2$43
Myriad Genetic Laboratories, Inc.2$42
Servier Pharmaceuticals LLC2$36
Exelixis Inc.2$36
Taiho Oncology, Inc.2$35
CTI Biopharma Corp.2$34
Sumitomo Pharma America, Inc.2$32
Deciphera Pharmaceuticals Inc.1$32
Myovant Sciences Inc.2$31
Pharmacyclics LLC, An Abbvie Company1$27
Recordati_rare_diseases_inc.1$23
Boehringer Ingelheim1$20
Karyopharm Therapeutics Inc.1$18
Macrogenics, Inc.1$17
Alnylam Pharmaceuticals Inc.1$17
Mirati Therapeutics, Inc.1$16
Foundation Medicine, Inc.1$15
Morphosys, US Inc.1$15
Azurity Pharmaceuticals, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,101 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$13,563
Medicare patients
96
Services billed
149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban21$18,724
Ondansetron OdtOndansetron29$1,437
Anastrozole34$750
Letrozole11$548
Prednisone13$184
Levofloxacin11$46

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$573$18,72421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.

Other family in Spring Hill

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →